Skip to main content
SpringerLink
Log in

Novel Cytotoxic Agents in the Management of Lung Cancer

  • Chapter
Tumors of the Chest

  • 812 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology 2004; 18:3.

    PubMed  Google Scholar 

  2. Spigel DR, Anthony Greco F. Chemotherapy in metastatic and locally advanced non-small cell lung cancer. Semin Surg Oncol 2003; 21:98.

    PubMed  Google Scholar 

  3. NSCLCCG. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 53 randomized clinical trials. BMJ 1995; 311:899.

    Google Scholar 

  4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379.

    PubMed  CAS  Google Scholar 

  5. Ettinger DS. Is there a preferred combination chemotherapy regimen for metastatic in non-small cell lung cancer? Oncologist 2002; 7:226.

    PubMed  CAS  Google Scholar 

  6. Wozniak AJ, Crowley JJ, Balcerzak, et al. Randomized trial comparing cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:2459.

    PubMed  CAS  Google Scholar 

  7. Sandier AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cosplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18:122.

    Google Scholar 

  8. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18:3390.

    PubMed  CAS  Google Scholar 

  9. Lilenbaum RC, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21:1a.

    Google Scholar 

  10. Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002; 38:S13.

    Google Scholar 

  11. Manegold C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 2001;34:S165.

    PubMed  Google Scholar 

  12. Thatcher N. Chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2001;34:S171.

    PubMed  Google Scholar 

  13. ASCO. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15:2996.

    Google Scholar 

  14. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 2001;357:1478.

    PubMed  CAS  Google Scholar 

  15. Kosmidis PA. A randomized phase III trial of paclitaxel plus carboplatin vs paclitaxel plus gemcitabine in advanced NSCLC. A preliminary analysis. Lung Cancer 2000; 29:S147.

    Google Scholar 

  16. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 335:479.

    Google Scholar 

  17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92.

    PubMed  CAS  Google Scholar 

  18. Giaccone G. Targeted therapy in non-small cell lung cancer. Lung Cancer 2002; 38:S29.

    PubMed  Google Scholar 

  19. Gridelli C. Targeted therapy in the treatment of non-small cell lung cancer: reality and hopes. Curr Opin Oncol 2004; 16:126.

    PubMed  Google Scholar 

  20. Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38:S5.

    Google Scholar 

  21. Kris MG. What does chemotherapy have to offer patients with advance-stage non-small cell lung cancer? Semin Oncol 1998; 25(suppl 8):1.

    PubMed  CAS  Google Scholar 

  22. Rigas JR. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Semin Oncol 1998;25(suppl 8):5.

    PubMed  CAS  Google Scholar 

  23. Misser JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000; 35:75.

    Google Scholar 

  24. Kosmidis PA, Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer 2003; 41:S123.

    PubMed  Google Scholar 

  25. Faivre S, Raymond E, Chapman W, et al. Lesion in cellular DNA and apoptosis induced by oxaliplatin. Proc Am Assoc Cancer Res 1997; 16:809A.

    Google Scholar 

  26. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25:299.

    PubMed  CAS  Google Scholar 

  27. Caussanel JP, Levi F, Brienza S, et al. Phase I study of 5-day continuous venous infusion oxaliplatin at circadian rhythm modulated rate with constant rate. J Nat Cancer Inst 1990; 82:1046.

    PubMed  CAS  Google Scholar 

  28. Monnet I, Brienza S, Hurget F, et al. Phase II study of oxaliplatin in poor prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 1998; 34:1124.

    PubMed  CAS  Google Scholar 

  29. Monnet I, Soulie P, de Cremoux H, et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:458.

    PubMed  CAS  Google Scholar 

  30. Faivre S, Le Chevalier T, Monnerat C, et al. Phase I–II and pharmacokinetic study of gemcitabine combined with ox aliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13:1479.

    PubMed  CAS  Google Scholar 

  31. Bidoli P, Stani SC, Mariani L, et al. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer 2004; 43:203.

    PubMed  Google Scholar 

  32. Franciosi V, Barbieri R, Vasini G, et al. The combination of gemcitabine and oxaliplatin (GEM-OXAL) is feasible inpatients with poor prognosis advanced non-small-cell lung cancer. Results of a phase II study. Eur J Cancer 2001;37:6.

    Google Scholar 

  33. Kouroussis C, Agelaki S, Mavroudis D, et al. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 2003; 23(1B):785.

    PubMed  CAS  Google Scholar 

  34. Winegarden JD, Mauer AM, Otterson GA, et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004; 15:915.

    PubMed  CAS  Google Scholar 

  35. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol 2004; 15:1123.

    PubMed  CAS  Google Scholar 

  36. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361:2235.

    PubMed  CAS  Google Scholar 

  37. Chinsoo Cho L, Hak Choy MS. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology 2004; 18:S29.

    Google Scholar 

  38. Schiller JH. Future role of topotecan in the treatment of lung cancer. Oncology 2001;61(suppl 1):55.

    PubMed  CAS  Google Scholar 

  39. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Gan To Kagaku Ryoho 1990; 17:115.

    PubMed  CAS  Google Scholar 

  40. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991;21:1164.

    Google Scholar 

  41. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 in primary lung cancer. Gan To Kagaku Ryoho 1991;18:607.

    PubMed  CAS  Google Scholar 

  42. Douillard J, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14:365.

    Google Scholar 

  43. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Group. Gan To Ka gaku Ryoho 1991;18:1013.

    CAS  Google Scholar 

  44. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10:16.

    PubMed  CAS  Google Scholar 

  45. Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16:461a.

    Google Scholar 

  46. Sanchez R, Esteban E, Palacio I, et al. Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs 2003; 21:459.

    PubMed  CAS  Google Scholar 

  47. Masuda N, Fukuoka M, Takada Y, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992; 10:1775.

    PubMed  CAS  Google Scholar 

  48. Mori K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1999; 43:467.

    PubMed  CAS  Google Scholar 

  49. DeVore RF, Johnson DH, Crawford, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 1999; 17:2710.

    PubMed  CAS  Google Scholar 

  50. Ando M, Kobayashi K, Yoshimura A, et al. Weekly admin istration of irinotecan (CPT-11) for refractory or relapsed non-small cell lung cancer. Lung Cancer 2004; 44:121.

    PubMed  Google Scholar 

  51. Kakolyris S, Kouroussis C, Souglakos J, et al. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34(suppl 4):S71.

    PubMed  Google Scholar 

  52. Ueoka H, Tanimoto M, Kiura K, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br J Cancer 2001;85:9.

    PubMed  CAS  Google Scholar 

  53. Negoro S, Masuda N, Takada Y, et al. Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. Br J Cancer 2003; 88:335.

    PubMed  CAS  Google Scholar 

  54. Takeda K, Negoro S, Takifuji N, et al. Dose escalation study of irinotecan combined with carboplatin for ad vanced non-small cell lung cancer. Cancer Chemother Pharmacol 2001;48:104.

    PubMed  CAS  Google Scholar 

  55. Kinoshita A, Fukuda M, et al. A phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:268b.

    Google Scholar 

  56. Takeda K, Takifuji N, Uejima H, et al. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer 2002; 38:303.

    PubMed  Google Scholar 

  57. Fukuda M, Oka M, Soda H, et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small cell lung cancer. Cancer Chemother Pharmacol 2004; 56:573.

    Google Scholar 

  58. Read W, McLeod H, Govindan R. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. Oncology (Hunt) 2004; 18(suppl 4):15.

    Google Scholar 

  59. Hotta K, Ueoka H, Kiura K, et al. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 45:77.

    PubMed  Google Scholar 

  60. Yamada K, Ikehara M, Tanaka G, et al. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 2004; 66:94.

    PubMed  CAS  Google Scholar 

  61. Masuda N, Negoro S, Kudoh S, et al. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18:2996.

    PubMed  CAS  Google Scholar 

  62. Nogami N, Harita S, Ueoka H, et al. Phase I study of docetaxel and irinotecan in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 45:85.

    PubMed  Google Scholar 

  63. Wachters FM, Groen HJ, Biesma B, et al. A randomized phase III trial docetaxel vs docetaxel and irinotecan in patients with stage Illb-IV non-small cell lung cancer who failed first-line treatment. Br J Cancer 2005; 92:15.

    PubMed  CAS  Google Scholar 

  64. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel and irinotecan as second-line treatment in advanced non-small cell lung cancer: a randomized phase II trial. Ann Oncol 2005; 16:294.

    PubMed  CAS  Google Scholar 

  65. Kakolyris SS, Kouroussis C, Koukourakis M, et al. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 2002; 22:1891.

    PubMed  CAS  Google Scholar 

  66. Nishio M, Ohyanagi F, Taguch F, et al. Phase I study of combination chemotherapy with gemcitabine and irinote can for non-small cell lung cancer. Lung Cancer 2005; 48:115.

    PubMed  Google Scholar 

  67. Pectasides D, Mylonakis N, Farmakis D, et al. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based chemotherapy. A phase II study. Anticancer Res 2003; 23:4205.

    PubMed  CAS  Google Scholar 

  68. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan in the second-line treat ment of patients with advanced non-small cell lung cancer previously treated with docetaxel and cisplatin: a multicentre, randomized, phase II study. Br J Cancer 2004; 91:482.

    PubMed  CAS  Google Scholar 

  69. Socinski MA, Sandier AB, Miller LL, et al. Phase I study of the combination of irinotecan, paclitaxel, and carbopla tin in patients with advanced non-small cell lung cancer. J Clin Oncol 2001;19:1078.

    PubMed  CAS  Google Scholar 

  70. _Socinski MA, Sandier AB, Miller LL, et al. Irinotecan (CPT-11) in triplet combinations in patients with ad vanced non-small cell lung cancer: a review and report of a phase I/II trial. Clin Lung Cancer 2001;2(suppl 2):S26.

    PubMed  Google Scholar 

  71. Socinski MA, Sandier AB, Israel VK, et al. Phase II trial of irinotecan, paclitaxel, and carboplatin in patients with previously untreated stage IIIB/IV non-small cell lung car cinoma. Cancer 2002; 95:1520.

    PubMed  CAS  Google Scholar 

  72. Pectasides D, Visvikis A, Kouloubinis A, et al. Weekly che motherapy with carboplatin, docetaxel and irinotecan in advanced non-small cell lung cancer: a phase II study. Eur J Cancer 2002; 38:1194.

    PubMed  CAS  Google Scholar 

  73. Stewart D. Update in the role of topotecan in the treat ment of non-small cell lung cancer. Oncologist 2004; 9(Suppl 4):43.

    PubMed  CAS  Google Scholar 

  74. Rowinski EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647.

    Google Scholar 

  75. Kakolyris S, Kouroussis C, Souglakos J, et al. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology 2001;61:265.

    PubMed  CAS  Google Scholar 

  76. Lynch TJ, Kalish L, Strauss G, et al. Phase II study of to potecan in metastatic non-small cell lung cancer. J Clin Oncol 1994; 12:347.

    PubMed  Google Scholar 

  77. Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14:503.

    PubMed  CAS  Google Scholar 

  78. Weitz JJ, Marschke RF, Sloan JA, et al. A randomized phase II trial of two schedules of topotecan for the treat ment of advanced non-small cell lung cancer. Lung Cancer 2000; 28:157.

    PubMed  CAS  Google Scholar 

  79. Mainwaring PN, Nicolson MC, Hickish T, et al. Continu ous infusional topotecan in advanced breast and non-small cell lung cancer: no evidence of increased efficacy. Br J Cancer 1997; 76:1636.

    PubMed  CAS  Google Scholar 

  80. Kindler HL, Kris MG, Smith IE, et al. Phase II trial of to potecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 1998; 21:438.

    PubMed  CAS  Google Scholar 

  81. White SC, Cheeseman S, Thatcher N, et al. Phase II trial of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 2000; 6:868.

    PubMed  CAS  Google Scholar 

  82. Raymond E, Burris HA, Rowinski EK, et al. Phase I study of daily times five topotecan and single injection of cis platin in patients with previously untreated non-small cell lung carcinoma. Ann Oncol 1997; 8:1003.

    PubMed  CAS  Google Scholar 

  83. Pujol JL, Pawel J, Tumolo S, et al. Preliminary results of combined therapy with topotecan and carboplatin in ad vanced non-small cell lung cancer. Oncology 2001;61(suppl 1):47.

    PubMed  CAS  Google Scholar 

  84. Rinaldi D, Lormand N, Brierre J, et al. A phase I–II trial of topotecan and gemcitabine in patients with previously untreated, advanced non-small cell lung cancer (LOA-3). Cancer Invest 2001;19:467.

    PubMed  CAS  Google Scholar 

  85. Rinaldi D, Lormand N, Brierre J, et al. A phase II trial of topotecan and gemcitabine in patients with previously un treated advanced nonsmall cell lung carcinoma. Cancer 2002; 15:1274.

    Google Scholar 

  86. Dabrow MB, Francesco MR, Gilman PB, et al. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer (LOA-3). Cancer Invest 2003; 21:517.

    PubMed  CAS  Google Scholar 

  87. Joppert MG, Garfield DH, Gregurich MA, et al. A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003; 39:215.

    PubMed  CAS  Google Scholar 

  88. Stupp R, Bodmer A, Duvoisin B, et al. Is cisplatin required for the treatment of non-small cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 2001;61(suppl 1):35.

    PubMed  CAS  Google Scholar 

  89. Dobbs T, Eckart JR, Gordon NH, et al. Oral topotecan (OT) and intravenous paclitaxel (P) in patients with ad vanced non-small cell lung cancer (NSCLC): a phase I/II study. Proc Am Soc Clin Oncol 2000; 19:522a.

    Google Scholar 

  90. Eckart JR. Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small cell lung cancer. Oncology 2001;61(suppl l):30.

    Google Scholar 

  91. Guarino MJ, Schneider CJ, Grubbs SS, et al. A dose-escalation study of weekly topotecan, cisplatin and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. Oncologist 2002; 7:509.

    PubMed  CAS  Google Scholar 

  92. Kelly K. New chemotherapy agents for small-cell lung cancer. Chest 2000; 117:156.

    Google Scholar 

  93. Schiller J. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61(suppl 1):3.

    PubMed  CAS  Google Scholar 

  94. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46:516.

    PubMed  CAS  Google Scholar 

  95. Adjei AA. Management of small-cell cancer of the lung. Curr Opin Pulm Med 2000; 6:384.

    PubMed  CAS  Google Scholar 

  96. Miklos S, Argiris A, Murren JR. Progress in the therapy of small-cell lung cancer. Crit Rev Oncol Hematol 2004; 49:119.

    Google Scholar 

  97. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small-cell carcinoma. Cancer 1979; 44:406.

    PubMed  CAS  Google Scholar 

  98. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83:8.

    PubMed  CAS  Google Scholar 

  99. Chrystal K, Cheong J, Harper P. Chemotherapy of small-cell lung cancer: state of the art. Curr Opin Oncol 2004; 16:136.

    PubMed  Google Scholar 

  100. Sudstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 2002; 20:4665.

    Google Scholar 

  101. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small-cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30:23.

    PubMed  CAS  Google Scholar 

  102. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282.

    PubMed  CAS  Google Scholar 

  103. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group. Ann Oncol 1994; 5:601.

    PubMed  CAS  Google Scholar 

  104. Kosmidis PA, Samantas E, Fountzilas F, et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small-cell lung cancer: a randomized phase III study. HECOG for lung cancer trials. Semin Oncol 1994; 21(suppl 6):23.

    PubMed  CAS  Google Scholar 

  105. Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16:27.

    PubMed  Google Scholar 

  106. Anupama K, Hansen H. Treatment of small-cell lung cancer. Crit Rev Oncol Hematol 2004; 52:117.

    Google Scholar 

  107. Stupp R, Monnerat C, Turrisi AT. Small-cell lung cancer: state of the art and future perspectives. Lung Cancer 2004; 45:105.

    PubMed  Google Scholar 

  108. Simon GR. Small-cell lung cancer. Chest 2003; 123:259S.

    PubMed  Google Scholar 

  109. Spira A Ettinger D. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379.

    PubMed  CAS  Google Scholar 

  110. Thatcher N, Eckart J, Green M. Options for first and second line therapy in small-cell lung cancer: a workshop discussion. Lung Cancer 2003; 41(suppl 4):S37.

    PubMed  Google Scholar 

  111. Okuna SH, Jett JR. Small-cell lung cancer: current therapy and promising new regimens. Oncologist 2002; 7:234.

    Google Scholar 

  112. Tjan-Heijnen VC, Wagener DJ, Postmus PE. An analysis of chemotherapy dose and dose intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002; 13:1519.

    PubMed  CAS  Google Scholar 

  113. Schiller J. Future role of topotecan in the treatment of lung cancer. Oncology 2004; 61(suppl 1):55.

    Google Scholar 

  114. Rowinski EK, Grochow LD, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647.

    Google Scholar 

  115. Saltz S, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt to dose intensification using recombinant granulocyte colony stimulating factor. J Natl Cancer Inst 1993; 85:1499.

    PubMed  CAS  Google Scholar 

  116. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4:673.

    PubMed  CAS  Google Scholar 

  117. Chinsoo Cho L, Hak Choy MS. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology 2004; 18(suppl):29.

    PubMed  Google Scholar 

  118. Schiller JH, Kim KM, Hufson P, et al. Phase II study of topotecan in patients with extensive small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14:2345.

    PubMed  CAS  Google Scholar 

  119. Eckart J, Gralla R, Palmer MC, et al. Topotecan (T) as second line therapy in patients with small-cell lung cancer (SCLC): a phase II study. Ann Oncol 1996; 7(suppl 5):107.

    Google Scholar 

  120. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan in relapsed small cell lung cancer (SCLC): a multicentre phase II study. Lung Cancer 1997; 18(suppl 1):35.

    Google Scholar 

  121. Ardizzoni A, Hansen H, Dombernowsky P, et al. for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Devel opment Office, and the Lung Cancer Cooperative Group. Topotecan, a new active drug in the second line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15:2090.

    PubMed  CAS  Google Scholar 

  122. Perez-Soler R, Glisson BS, Lee JS, et al. Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc Am Soc Clin Oncol 1995; 14:355.

    Google Scholar 

  123. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658.

    Google Scholar 

  124. Ardizzoni A, Manegold C, Debruyne C, et al. EORTC LCCG phase II study of topotecan in combination with cisplatin as second line chemotherapy of sensitive and refractory small cell lung cancer (SCLC). Lung Cancer 2000; 29:51.

    Google Scholar 

  125. Samantas E, Giannelou M, Onyenadum A, et al. A phase II study of cisplatin and topotecan as second line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21:218b.

    Google Scholar 

  126. Mavroudis D, Veslemes M, Kouroussis C, et al. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC): a multicentre phase II study. Lung Cancer 2002; 38:59.

    PubMed  CAS  Google Scholar 

  127. Mavroudis D, Pavlakou G, Blazoyiannakis G, et al. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicentre phase II study. Lung Cancer 2003; 39:71.

    PubMed  CAS  Google Scholar 

  128. O’Neill P, Clark PI, Smith D, et al. A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology 2001; 61(suppl 1):25.

    PubMed  CAS  Google Scholar 

  129. Mok TS, Wong H, Zee B, et al. A phase I–II study of sequential administration of topotecan and oral etoposide (topo-isomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer 2002; 95:1511.

    PubMed  CAS  Google Scholar 

  130. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 — a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:2114.

    PubMed  CAS  Google Scholar 

  131. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743.

    Google Scholar 

  132. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative in patients with primary lung cancer. Jpn J Cancer Chemother 1991;18:1013.

    CAS  Google Scholar 

  133. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225.

    PubMed  CAS  Google Scholar 

  134. Le Chevalier T, Ibrahim N, Chorny P, et al. A phase II study of irinotecan (CPT-11) in patients with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol 1997; 16:450A.

    Google Scholar 

  135. Kudoh S, Fujiwara Y, Takad Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small cell lung cancer. J Clin Oncol 1998; 16:1068.

    PubMed  CAS  Google Scholar 

  136. Okishio K, Furuse K, Kawahara M, et al. A phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in previously treated small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17:497a.

    Google Scholar 

  137. Nakanishi Y, Takayama K, Takanoi K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Proc Am Soc Clin Oncol 1999; 22:399.

    CAS  Google Scholar 

  138. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002; 37:319.

    PubMed  Google Scholar 

  139. Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with refractory or relapsed small cell lung cancer. Lung Cancer 2003; 40:333.

    PubMed  Google Scholar 

  140. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85.

    PubMed  CAS  Google Scholar 

  141. Francis PA, Kris MG, Rigas JR, et al. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 1995; 12(suppl 1):S163.

    PubMed  Google Scholar 

  142. Vaishampayan U, Parchment R, Jasti BR, et al. Taxanes: an overview of the pharmacokinetics and pharmacody-namics. Urology 1999; 54(suppl 6A):22.

    PubMed  CAS  Google Scholar 

  143. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive disease small-cell lung cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1430.

    PubMed  CAS  Google Scholar 

  144. Kirschling RJ, Jung SH, Jett JR, et al. for the North Cen tral Cancer Treatment Group. A phase II trial of Taxol and GCSF in previously untreated patients with extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1994; 13:326.

    Google Scholar 

  145. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 72:347.

    Google Scholar 

  146. Nair S, Marchte R, Grill J, et al. A phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC). Proc Am Soc Clin Oncol 1997; 16:454A.

    Google Scholar 

  147. Green HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: a non-cross resistant schedule. J Clin Oncol 1999; 17:927.

    Google Scholar 

  148. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 2001; 84:38.

    PubMed  CAS  Google Scholar 

  149. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 2001; 19:1320.

    PubMed  CAS  Google Scholar 

  150. Kakolyris S, Mavroudis D, Tsavaris N, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicentre phase II study. Ann Oncol 2001; 12:193.

    PubMed  CAS  Google Scholar 

  151. Jett JR, Day R, Levitt M, et al. Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 1997; 18(suppl 1):13.

    Google Scholar 

  152. West W, Birch R, Schnell F, et al. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncologist 2003; 8:76.

    PubMed  CAS  Google Scholar 

  153. Ramalingam S, Belani CP, Day R, et al. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol 2004; 15:247.

    PubMed  CAS  Google Scholar 

  154. Kelly K, Wood ME, Bun PA Jr, et al. A phase I study of cisplatin, etoposide and paclitaxel (PET) in small cell lung cancer. Lung Cancer 1997; 18(suppl 1):28.

    Google Scholar 

  155. Glisson BS, Kurie JM, Fox NJ, et al. Phase I–II study of cisplatin, etoposide and paclitaxel (PIT) in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1997; 16:455A.

    Google Scholar 

  156. Mavroudis D, Papadakis E, Veslemes M, et al. A multicentre clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12:463.

    PubMed  CAS  Google Scholar 

  157. Hainsworth JD, Gray JR, Stroup S, et al. Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose intensities. J Clin Oncol 1997; 15:3463.

    Google Scholar 

  158. Neill HB, Miller AA, Clamon GH, et al. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony stimulating factor in patients with stage IIIB and IV non-small-cell lung cancer and extensive disease small-cell lung cancer. Semin Oncol 1997; 24(suppl 12):S130.

    Google Scholar 

  159. Vietez JM, Valladares M, Gracia M, et al. Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer 2003; 39:77.

    Google Scholar 

  160. Hainsworth JD, Morrissey L, Scullin D, et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma. A phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002; 94:2426.

    PubMed  CAS  Google Scholar 

  161. Socinski M, Neubauer M, Olivares J, et al. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer 2003; 40:91.

    PubMed  Google Scholar 

  162. Jett JR, Hatfield AK, Hilman S, et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated extensive-stage small cell lung cancer. Cancer 2003; 10:2498.

    Google Scholar 

  163. Hesketh PJ, Crowley JJ, Burris HA, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer. A Southwest Oncology Group phase II trial. Cancer J Sci Am 1999; 5:237.

    PubMed  CAS  Google Scholar 

  164. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994; 30A:1058.

    PubMed  CAS  Google Scholar 

  165. Lianes P, Moreno-Nogueira JA, Cardenal F, et al. Multicentre phase II clinical trial of docetaxel (D) in combination with cisplatin (P) in first line chemotherapy for small cell lung cancer extensive disease: final results. Proc Am Soc Clin Oncol 2001; 20; 309.

    Google Scholar 

  166. Skarlos DV, Dimopoulos AM, Kosmidis P, et al. Docetaxel and gemcitabine combination, as first-line treatment in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer 2003; 41:107.

    PubMed  Google Scholar 

  167. Agelaki S, Veslemes M, Syrigos K, et al. A multicentre phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004; 43:329.

    PubMed  Google Scholar 

  168. Rang HP, Dale MM, et al. Drugs used in cancer chemotherapy. In: Rang HP (ed) Pharmacology. New York: Churchill Livingston, 2003: 6.8.

    Google Scholar 

  169. Cormier Y, Eisenhauer E, Muldal E, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5:283.

    PubMed  CAS  Google Scholar 

  170. van der Lee I, Smit EF, van Puten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001; 12:557.

    PubMed  Google Scholar 

  171. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Group Trial 1597. J Clin Oncol 2003; 21:1550.

    PubMed  CAS  Google Scholar 

  172. Hoang T, Kim T, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003; 42:97.

    PubMed  Google Scholar 

  173. James L, Rudd R, Gower N, et al. A phase III randomized comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2002; 21:2193.

    Google Scholar 

  174. Vansteenkistee J, Gatzemeier U, Manegold C, et al. Gemcitabine plus etoposide in chemonaive extensive disease small cell lung cancer: a multicentre phase II study. Ann Oncol 2001; 12:835.

    Google Scholar 

  175. Agelaki S, Syrigos K, Christofyllakis C, et al. A multicentre phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 2004; 66:192.

    PubMed  CAS  Google Scholar 

  176. Higano CS, Crowley JJ, Veith RV, et al. A phase II study of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Invest New Drugs 1997; 15:153.

    PubMed  CAS  Google Scholar 

  177. Jaseem J, Karnicka-Mlodwowska H, van Pottelsberge C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Can cer Cooperative Group. Eur J Cancer 1993; 12:1720.

    Google Scholar 

  178. Gridelli C, Perrone F, Iannelio GP, et al. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol 1998; 16:1414.

    PubMed  CAS  Google Scholar 

  179. Richardet E, Carranza L, Uribe A, et al. Phase II study: cisplatin (C) + etoposide (E) + Navelbine (N) in small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14:373a.

    Google Scholar 

  180. Negoro T, Takada Y, Yokota S. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline in extensive stage small cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group trial. Proc Am Soc Clin Oncol 1998; 17:704A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece

    Ifigenia Tzannou

  2. Cancer Research UK Centre for Cell and Molecular Biology, Institute of Cancer Research, London, UK

    Kevin J. Harrington

  3. Oncology Unit, Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos

Authors
  1. Ifigenia Tzannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin J. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantinos N. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Tzannou, I., Harrington, K.J., Syrigos, K.N. (2006). Novel Cytotoxic Agents in the Management of Lung Cancer. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_34

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_34

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation